UnitedHealth Group
UNH
$414.40
-1.68%
UnitedHealth Group is a diversified healthcare conglomerate operating through two primary platforms: UnitedHealthcare, which provides health insurance coverage to approximately 51 million members globally, and Optum, which offers healthcare services, pharmacy benefit management, and data analytics. As one of the largest private health insurers in the United States, UnitedHealth holds a dominant market position, leveraging its integrated model to drive efficiency and scale across the healthcare value chain. The current investor narrative centers on the company's operational recovery following a challenging 2025, marked by a sharp rebound in earnings and a significant stock rally, while also grappling with regulatory scrutiny from a Department of Justice investigation and the broader implications of government healthcare policy on its growth trajectory.…
UNH
UnitedHealth Group
$414.40
Related headlines
Investment Opinion: Should I buy UNH Today?
Based on the analysis, UNH is rated a Buy. The thesis is that the company's operational recovery, driven by improved Medicare rates and cost management, will continue, leading to EPS growth to $34.29 and a re-rating toward the average target of $475.23. The consensus recommendation is 'buy' with a mean rating of 1.59, and the stock offers 14.7% upside to the average target.
Sign up to view all
UNH 12-Month Price Forecast
The AI assessment is bullish with medium confidence, as the data indicates a strong operational recovery and attractive valuation. However, the unresolved DOJ investigation and decelerating revenue growth temper confidence. If the investigation is resolved favorably and growth accelerates, the stance would upgrade to high confidence. Conversely, if regulatory issues worsen or earnings disappoint, the stance would downgrade to neutral.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on UnitedHealth Group's 12-month outlook, with a consensus price target around $475.23 and implied upside of +14.7% versus the current price.
Average Target
$475.23
0 analysts
Implied Upside
+14.7%
vs. current price
Analyst Count
—
covering this stock
Price Range
$313 - $529
Analyst target range
The target price range spans from a low of $313.00 to a high of $529.00, indicating a wide dispersion of 69% between the lowest and highest targets, reflecting significant uncertainty about the company's future performance. The high target of $529 assumes continued operational recovery, potential resolution of regulatory issues, and robust growth in both insurance and Optum segments, while the low target of $313 suggests concerns about margin compression, competitive pressures, or adverse government policy changes. Recent institutional ratings have been predominantly positive, with no downgrades in the last month, and the stock's strong rally off its lows has been supported by better-than-expected Medicare reimbursement rates and improved Q1 earnings, though the unresolved DOJ investigation remains a key overhang that could limit upside.
Bulls vs Bears: UNH Investment Factors
UnitedHealth presents a compelling recovery story with strong Q1 2026 earnings, a dominant market position, and a reasonable forward valuation. However, the unresolved DOJ investigation and decelerating revenue growth introduce significant uncertainty. The bull case is currently stronger, supported by analyst consensus and operational rebound, but the bear case hinges on regulatory and policy risks that could derail the recovery. The key tension is whether the earnings recovery is sustainable and whether regulatory overhangs will be resolved favorably, as this will determine if the stock can reach the average target of $475 or fall back to the low of $313.
Bullish
- Strong earnings recovery in Q1 2026: Q1 2026 EPS of $6.90 rebounded sharply from the depressed $0.01 in Q4 2025, signaling a return to normalized profitability. Net income of $6.28 billion and operating margin of 8.0% demonstrate operational recovery, supporting the forward PE of 18.47x.
- Dominant market position and scale: With 51 million members and a market cap of $382.8 billion, UnitedHealth is the largest private health insurer, providing a competitive moat. Revenue of $111.72 billion in Q1 2026 reflects its massive scale, enabling cost efficiencies and pricing power.
- Attractive forward valuation: The forward PE of 18.47x is a 26% discount to the trailing PE of 24.95x, implying the market expects significant earnings growth. Analysts estimate EPS of $34.29 for the next fiscal year, which would justify the current price if achieved.
- Defensive characteristics with low beta: With a beta of 0.633, UNH is less volatile than the market, making it a defensive holding. The 1-year price change of +66.05% versus the S&P 500's +18.19% shows strong relative strength, appealing to risk-averse investors.
Bearish
- Unresolved DOJ investigation: The Department of Justice investigation remains an overhang, with potential fines or operational restrictions. News highlights that the unresolved probe limits upside, and any adverse findings could trigger a sharp sell-off.
- Decelerating revenue growth: Q1 2026 revenue growth was only 1.96% YoY, down from 8.5% in Q4 2024. This deceleration suggests maturing core markets and potential saturation, which may not support the premium valuation.
- High payout ratio and limited dividend growth: The payout ratio of 65.7% leaves little room for dividend increases, and the yield of 2.64% is modest. This may disappoint income-focused investors, especially if earnings growth slows.
- Vulnerability to government policy changes: As a major Medicare and Medicaid provider, UNH is exposed to reimbursement rate changes. The 2025 earnings dip was partly due to lower Medicare rates, and future policy shifts could pressure margins.
UNH Technical Analysis
UnitedHealth's stock has demonstrated a robust long-term uptrend, with a 1-year price change of +66.05%, significantly outperforming the S&P 500's +18.19% over the same period. The current price of $414.40 sits at approximately 89.8% of its 52-week range (between $234.60 low and $461.62 high), indicating the stock is trading near its highs, reflecting strong momentum and investor confidence, though it also suggests potential overextension in the short term. The stock's beta of 0.633 indicates it is less volatile than the broader market, making it a relatively defensive holding within the healthcare sector.
Beta
0.63
0.63x market volatility
Max Drawdown
-30.0%
Largest decline past year
52-Week Range
$237-$462
Price range past year
Annual Return
+66.1%
Cumulative gain past year
| Period | UNH Return | S&P 500 |
|---|---|---|
| 1m | -2.8% | +0.3% |
| 3m | +12.4% | +4.0% |
| 6m | +44.4% | +8.3% |
| 1y | +66.1% | +20.2% |
| ytd | +23.2% | +9.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
UNH Fundamental Analysis
UnitedHealth's revenue trajectory has been steadily growing, with the most recent quarter (Q1 2026) reporting revenue of $111.72 billion, a 1.96% year-over-year increase from $109.58 billion in Q1 2025. While growth has decelerated from the 8.5% YoY growth seen in Q4 2024, the company has maintained consistent revenue expansion across recent quarters, with Q2 2025 at $111.62 billion and Q3 2025 at $113.16 billion. The revenue growth is primarily driven by the UnitedHealthcare segment, which contributed $82.99 billion in revenue, while OptumHealth added $4.58 billion, indicating the insurance business remains the core growth engine, though Optum's higher-margin services are increasingly important.
Quarterly Revenue
$111.7B
2026-03
Revenue YoY Growth
+2.0%
YoY Comparison
Gross Margin
22.7%
Latest Quarter
Free Cash Flow
$19.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is UNH Overvalued?
Given UnitedHealth's positive net income, the price-to-earnings (PE) ratio is the most appropriate valuation metric. The trailing PE stands at 24.95x, while the forward PE is 18.47x, implying the market expects significant earnings growth, with the forward multiple representing a 26% discount to the trailing multiple. This gap suggests investors are pricing in a strong earnings recovery, consistent with the company's recent operational improvements and analyst estimates of EPS growth to $34.29 for the upcoming fiscal year.
PE
25.0x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 19x~29x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
15.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks include a debt-to-equity ratio of 0.83, indicating moderate leverage, and a current ratio of 0.79, suggesting potential liquidity concerns. The company's net margin of 2.69% is thin, and Q4 2025 showed a net loss of $10 million, highlighting earnings volatility. However, free cash flow of $19.67 billion provides a cushion, and the payout ratio of 65.7% limits dividend flexibility. Revenue concentration in the insurance segment (74% of total) exposes UNH to healthcare utilization trends and pricing pressures.